Biomaterial-enhanced cell and drug delivery: lessons learned in the cardiac field and future perspectives
O'Neill, Hugh S. Gallagher, Laura B. O'Sullivan, Janice Whyte, William Curley, Clive Dolan, Eimear Hameed, Aamir O'Dwyer, Joanne Payne, Christina O'Reilly, Daniel
O'Neill, Hugh S.
Gallagher, Laura B.
O'Sullivan, Janice
Whyte, William
Curley, Clive
Dolan, Eimear
Hameed, Aamir
O'Dwyer, Joanne
Payne, Christina
O'Reilly, Daniel
Publication Date
2016-02-03
Keywords
biomaterials, cardiac tissue engineering, drug delivery, hydrogels, stem cell therapy, acute myocardial-infarction, chronic heart-failure, left-ventricular function, mesenchymal stem-cells, chronic ischemic cardiomyopathy, gelatin methacrylate hydrogels, rgd modified alginate, extracellular-matrix, 6-minute walk, intramyocardial injections
Type
Article
Downloads
Citation
O'Neill, Hugh S. Gallagher, Laura B.; O'Sullivan, Janice; Whyte, William; Curley, Clive; Dolan, Eimear; Hameed, Aamir; O'Dwyer, Joanne; Payne, Christina; O'Reilly, Daniel; Ruiz-Hernandez, Eduardo; Roche, Ellen T.; O'Brien, Fergal J; Cryan, Sally Ann; Kelly, Helena; Murphy, Bruce; Duffy, Garry P. (2016). Biomaterial-enhanced cell and drug delivery: lessons learned in the cardiac field and future perspectives. Advanced Materials 28 (27), 5648-5661
Abstract
Heart failure is a significant clinical issue. It is the cause of enormous healthcare costs worldwide and results in significant morbidity and mortality. Cardiac regenerative therapy has progressed considerably from clinical and preclinical studies delivering simple suspensions of cells, macromolecule, and small molecules to more advanced delivery methods utilizing biomaterial scaffolds as depots for localized targeted delivery to the damaged and ischemic myocardium. Here, regenerative strategies for cardiac tissue engineering with a focus on advanced delivery strategies and the use of multimodal therapeutic strategies are reviewed.
Funder
Publisher
Wiley-Blackwell
Publisher DOI
Rights
Attribution-NonCommercial-NoDerivs 3.0 Ireland